Andreas Prachalias
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Andreas Prachalias has a total of 56 co-authors. Here are the top co-authors by number of shared publications:
- Nigel Heaton
Institute of Liver Studies, King’s College Hospital NHS Foundation Trust, Denmark Hill, London SE5 9RS, UK
4 shared publications - Parthi Srinivasan
Institute of Liver Studies, Hepato-Pancreato-Biliary Surgery Department, King's College Hospital, Denmark Hill, SE5 9RS, London, UK
4 shared publications - Krishna Menon
Liver Transplant Surgery, Institute of Liver Studies, King's College Hospital, London, United Kingdom
3 shared publications - Deepak Joshi
Institute of Liver Studies King's College Hospital London UK
2 shared publications - Mohamed Rela
The Institute of Liver Disease & Transplantation, Dr.Rela Institute & Medical Centre, Bharath Institute of Higher Education & Research, Chennai, India
2 shared publications - Wayel Jassem
Institute of Liver Studies, King’s College Hospital NHS Foundation Trust, London SE5 9RS, UK
2 shared publications
Latest Publications
- Open Access
- 28 April 2026
- Published by The Korean Association of Hepato-Biliary-Pancreatic Surgery in Annals of Hepato-Biliary-Pancreatic Surgery
- Vol. 30 (3) , 393-398
Left hepatectomy for chronic biopsy-induced intrahepatic arterioportal fistula with aneurysmal degeneration
Evangelia Florou, Michail Pizanias, Pauline Kane, Parthi Srinivasan, Andreas Prachalias. Ann Hepatobiliary Pancreat Surg -0001;0:. https://doi.org/10.14701/ahbps.26-061
- 28 April 2026
- Published by The Korean Association of Hepato-Biliary-Pancreatic Surgery in Annals of Hepato-Biliary-Pancreatic Surgery
- Vol. 30 (3) , 393-398
Open AccessLeft hepatectomy for chronic biopsy-induced intrahepatic arterioportal fistula with aneurysmal degeneration
Evangelia Florou, Michail Pizanias, Pauline Kane, Parthi Srinivasan, Andreas Prachalias. Ann Hepatobiliary Pancreat Surg -0001;0:. https://doi.org/10.14701/ahbps.26-061
- 16 February 2023
- Published by Wiley in Liver International
- Vol. 43 (5) , 1107-1119
Outcomes after liver transplantation using deceased after circulatory death donors: A comparison of outcomes in the UK and the US
Background and Aims: Identifying international differences in utilization and outcomes of liver transplantation (LT) after donation after circulatory death (DCD) donation provides a unique opportunity for benchmarking and population‐level insight.Methods: Adult (≥18 years) LT data between 2008 and 2018 from the UK and US were used to assess mortality and graft failure after DCD LT. We used time‐dependent Cox‐regression methods to estimate hazard ratios (HR) for risk‐adjusted short‐term (0–90 days) and longer‐term (90 days–5 years) outcomes.Results: One‐thousand five‐hundred‐and‐sixty LT receipts from the UK and 3426 from the US were included. Over the study period, the use of DCD livers increased from 15.7% to 23.9% in the UK compared to 5.1% to 7.6% in the US. In the UK, DCD donors were older (UK:51 vs. US:33 years) with longer cold ischaemia time (UK: 437 vs. US: 333 min). Recipients in the US had higher Model for End‐stage Liver Disease (MELD) scores, higher body mass index, higher proportions of ascites, encephalopathy, diabetes and previous abdominal surgeries. No difference in the risk‐adjusted short‐term mortality or graft failure was observed between the countries. In the longer‐term (90 days–5 years), the UK had lower mortality and graft failure (adj.mortality HR:UK: 0.63 (95% CI: 0.49–0.80); graft failure HR: UK: 0.72, 95% CI: 0.58–0.91). The cumulative incidence of retransplantation was higher in the UK (5 years: UK: 11.9% vs. 4.6%; p < .001).Conclusions: For those receiving a DCD LT, longer‐term post‐transplant outcomes in the UK are superior to the US, however, significant differences in recipient illness, graft quality and access to retransplantation were seen between the two countries.
- 16 February 2023
- Published by Wiley in Liver International
- Vol. 43 (5) , 1107-1119
Outcomes after liver transplantation using deceased after circulatory death donors: A comparison of outcomes in the UK and the US
Background and Aims: Identifying international differences in utilization and outcomes of liver transplantation (LT) after donation after circulatory death (DCD) donation provides a unique opportunity for benchmarking and population‐level insight.Methods: Adult (≥18 years) LT data between 2008 and 2018 from the UK and US were used to assess mortality and graft failure after DCD LT. We used time‐dependent Cox‐regression methods to estimate hazard ratios (HR) for risk‐adjusted short‐term (0–90 days) and longer‐term (90 days–5 years) outcomes.Results: One‐thousand five‐hundred‐and‐sixty LT receipts from the UK and 3426 from the US were included. Over the study period, the use of DCD livers increased from 15.7% to 23.9% in the UK compared to 5.1% to 7.6% in the US. In the UK, DCD donors were older (UK:51 vs. US:33 years) with longer cold ischaemia time (UK: 437 vs. US: 333 min). Recipients in the US had higher Model for End‐stage Liver Disease (MELD) scores, higher body mass index, higher proportions of ascites, encephalopathy, diabetes and previous abdominal surgeries. No difference in the risk‐adjusted short‐term mortality or graft failure was observed between the countries. In the longer‐term (90 days–5 years), the UK had lower mortality and graft failure (adj.mortality HR:UK: 0.63 (95% CI: 0.49–0.80); graft failure HR: UK: 0.72, 95% CI: 0.58–0.91). The cumulative incidence of retransplantation was higher in the UK (5 years: UK: 11.9% vs. 4.6%; p < .001).Conclusions: For those receiving a DCD LT, longer‐term post‐transplant outcomes in the UK are superior to the US, however, significant differences in recipient illness, graft quality and access to retransplantation were seen between the two countries.
P98 Formal regional referral networks optimize patient selection for liver transplantation
Introduction Unlike other conditions with high mortality (eg hepatocellular carcinoma (HCC)) chronic liver disease (CLD) patients (PTs) in the United Kingdom do not have standardised referral pathways. To improve access to liver transplantation (LT), King’s College Hospital (KCH) developed a network of satellite LT centres (SLTCs). We aimed to evaluate the impact of SLTCs in LT candidacy evaluation in CLD PTs and those within the established HCC pathway. Methods All PTs discussed at the KCH LT meeting between 10/2014-10/2019 were included. All second opinions from other centres and PTs without CLD or HCC were excluded. Geographic, referral (KCH, SLTC or conventional referrer (CR)), clinical, demographic and laboratory data were retrospectively recorded. HCC PTs had tumor related variables recorded. CLD and HCC PTs were analyzed separately. Univariate (UVA) and multivariate analyses (MVA) were utilized to assess the impact of SLTCs. Results 1102 assessments from CLD PTs (CR=512 SLTC=299 KCH=291) and 240 assessments from HCC PTs (CR=110 SLTC=72 KCH=58) were included. HCC PTs were not significantly more likely to be; referred from CRs/SLTCs/KCH, listed or have a contraindication to LT than CLD PTs. 725 CLD PTs were listed and 216 had contraindications to LT. Variables significantly associated with listing included; younger age, autoimmune liver diseases (AILD), biliary atresia (BA), previous LT, higher CLD prognostic scores, shorter referral to decision time and referral from SLTCs. Variables significantly negatively associated with listing included; non-alcoholic fatty liver disease (NAFLD), alcohol related liver disease (ARLD), hepatitis C and referral from CRs. MVA was utilized to demonstrate that referrals from SLTCs remained independently associated with listing (adjusted odds ratio (aOR) 2.92 (95% confidence interval (CI) 2.07-4.17)). Variables associated with contraindication to LT included; older age, ARLD, NAFLD, higher CLD prognostic scores and referral from CRs. Variables negatively associated with contraindication to LT included; AILD, BA, previous LT or referral from SLTC. MVA was utilized to demonstrate that referrals from SLTC remained independently negatively associated with contraindications (aOR 0.33 (95%CI 0.21-0.50)). 168 HCC patients were listed and 55 had contraindications to LT. No variables were significantly associated with listing including referrals from SLTC on UVA or MVA. Older HCC PTs were significantly more likely to have a contraindication to LT but referrals from SLTC did not influence likelihood on UVA or MVA. Conclusions Formal referral pathways through SLTCs improve PT selection and access to LT for PTs with CLD but do not impact on the well-established HCC pathway.
P98 Formal regional referral networks optimize patient selection for liver transplantation
Introduction Unlike other conditions with high mortality (eg hepatocellular carcinoma (HCC)) chronic liver disease (CLD) patients (PTs) in the United Kingdom do not have standardised referral pathways. To improve access to liver transplantation (LT), King’s College Hospital (KCH) developed a network of satellite LT centres (SLTCs). We aimed to evaluate the impact of SLTCs in LT candidacy evaluation in CLD PTs and those within the established HCC pathway. Methods All PTs discussed at the KCH LT meeting between 10/2014-10/2019 were included. All second opinions from other centres and PTs without CLD or HCC were excluded. Geographic, referral (KCH, SLTC or conventional referrer (CR)), clinical, demographic and laboratory data were retrospectively recorded. HCC PTs had tumor related variables recorded. CLD and HCC PTs were analyzed separately. Univariate (UVA) and multivariate analyses (MVA) were utilized to assess the impact of SLTCs. Results 1102 assessments from CLD PTs (CR=512 SLTC=299 KCH=291) and 240 assessments from HCC PTs (CR=110 SLTC=72 KCH=58) were included. HCC PTs were not significantly more likely to be; referred from CRs/SLTCs/KCH, listed or have a contraindication to LT than CLD PTs. 725 CLD PTs were listed and 216 had contraindications to LT. Variables significantly associated with listing included; younger age, autoimmune liver diseases (AILD), biliary atresia (BA), previous LT, higher CLD prognostic scores, shorter referral to decision time and referral from SLTCs. Variables significantly negatively associated with listing included; non-alcoholic fatty liver disease (NAFLD), alcohol related liver disease (ARLD), hepatitis C and referral from CRs. MVA was utilized to demonstrate that referrals from SLTCs remained independently associated with listing (adjusted odds ratio (aOR) 2.92 (95% confidence interval (CI) 2.07-4.17)). Variables associated with contraindication to LT included; older age, ARLD, NAFLD, higher CLD prognostic scores and referral from CRs. Variables negatively associated with contraindication to LT included; AILD, BA, previous LT or referral from SLTC. MVA was utilized to demonstrate that referrals from SLTC remained independently negatively associated with contraindications (aOR 0.33 (95%CI 0.21-0.50)). 168 HCC patients were listed and 55 had contraindications to LT. No variables were significantly associated with listing including referrals from SLTC on UVA or MVA. Older HCC PTs were significantly more likely to have a contraindication to LT but referrals from SLTC did not influence likelihood on UVA or MVA. Conclusions Formal referral pathways through SLTCs improve PT selection and access to LT for PTs with CLD but do not impact on the well-established HCC pathway.
P136 Endoscopic ultrasound: a highly effective tool in the investigation of lymphadenopathy of unknown cause
Introduction Endoscopic ultrasound (EUS) guided tissue acquisition is an indispensable tool in the diagnostic pathway of upper GI and hepatobiliary cancer. We sought to assess its utility in guiding patient management in patients presenting with lymphadenopathy of unknown cause. Methods Consecutive patients with lymphadenopathy undergoing EUS guided lymph node sampling were retrospectively analysed. Recorded variables included patient demographics, procedural characteristics, histological findings and patient management. Results 90 episodes (males n=51, 57%) were identified over a ten-year period. Median age at EUS was 62 years old (range 13-88 years old). Median size of lymph node sampled was 20mm (range 6-71mm), with a median of 2 passes (range 1-4). A 22 G needle was used in 62 (68.89%) of cases. The majority of lymph nodes sampled were from the peri-pancreatic area (n= 50, 56%), followed by peri-hepatic (n=15, 17%), celiac (n= 14, 16%), para-esophageal (n=4, 4.%), peri-gastric (n=3, 3%), mediastinum (n=2, 2%) and para-duodenal (n=2, 2%). The final diagnosis were benign lymphadenopathy (n= 31, 34%) followed by adenocarcinoma (n=23, 26%), lymphoma (n=6, 7%), tuberculosis (TB) (n=5, 6%), sarcoidosis (n=5, 6%), and neuroendocrine tumour (n=5, 6%). There was insufficient tissue for histological diagnosis in 15 (17%) cases. Sensitivity for malignancy was 78% with a specificity of 100%. Sensitivity for inflammatory disorders was 88%. All the cases with TB had a positive diagnosis. There were no complications associated with EUS guided sampling. Conclusions EUS is a highly safe and effective method of tissue acquisition in patient presenting with unexplained lymphadenopathy.
P136 Endoscopic ultrasound: a highly effective tool in the investigation of lymphadenopathy of unknown cause
Introduction Endoscopic ultrasound (EUS) guided tissue acquisition is an indispensable tool in the diagnostic pathway of upper GI and hepatobiliary cancer. We sought to assess its utility in guiding patient management in patients presenting with lymphadenopathy of unknown cause. Methods Consecutive patients with lymphadenopathy undergoing EUS guided lymph node sampling were retrospectively analysed. Recorded variables included patient demographics, procedural characteristics, histological findings and patient management. Results 90 episodes (males n=51, 57%) were identified over a ten-year period. Median age at EUS was 62 years old (range 13-88 years old). Median size of lymph node sampled was 20mm (range 6-71mm), with a median of 2 passes (range 1-4). A 22 G needle was used in 62 (68.89%) of cases. The majority of lymph nodes sampled were from the peri-pancreatic area (n= 50, 56%), followed by peri-hepatic (n=15, 17%), celiac (n= 14, 16%), para-esophageal (n=4, 4.%), peri-gastric (n=3, 3%), mediastinum (n=2, 2%) and para-duodenal (n=2, 2%). The final diagnosis were benign lymphadenopathy (n= 31, 34%) followed by adenocarcinoma (n=23, 26%), lymphoma (n=6, 7%), tuberculosis (TB) (n=5, 6%), sarcoidosis (n=5, 6%), and neuroendocrine tumour (n=5, 6%). There was insufficient tissue for histological diagnosis in 15 (17%) cases. Sensitivity for malignancy was 78% with a specificity of 100%. Sensitivity for inflammatory disorders was 88%. All the cases with TB had a positive diagnosis. There were no complications associated with EUS guided sampling. Conclusions EUS is a highly safe and effective method of tissue acquisition in patient presenting with unexplained lymphadenopathy.
- Open Access
- 29 October 2015
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 10 (10) , e0139791
Impact of Donation Mode on the Proportion and Function of T Lymphocytes in the Liver
Liver T-cells respond to the inflammatory insult generated during organ procurement and contribute to the injury following reperfusion. The mode of liver donation alters various metabolic and inflammatory pathways but the way it affects intrahepatic T-cells is still unclear. We investigated the modifications occurring in the proportion and function of T-cells during liver procurement for transplantation. We isolated hepatic mononuclear cells (HMC) from liver perfusate of living donors (LD) and donors after brain death (DBD) or cardiac death (DCD) and assessed the frequency of T-cell subsets, their cytokine secretion profile and CD8 T-cell cytotoxicity function, responsiveness to a danger associated molecular pattern (High Mobility Group Box1, HMGB1) and association with donor and recipient clinical parameters and immediate graft outcome. We found that T-cells in healthy human livers were enriched in memory CD8 T-cells exhibiting a phenotype of non-circulating tissue-associated lymphocytes, functionally dominated by more cytotoxicity and IFN-γ-production in DBD donors, including upon activation by HMGB1 and correlating with peak of post-transplant AST. This liver-specific pattern of CD8 T-cell was prominent in DBD livers compared to DCD and LD livers suggesting that it was influenced by events surrounding brain death, prior to retrieval. Mode of liver donation can affect liver T-cells with increased liver damage in DBD donors. These findings may be relevant in designing therapeutic strategies aimed at organ optimization prior to transplantation.
- 29 October 2015
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 10 (10) , e0139791
Open AccessImpact of Donation Mode on the Proportion and Function of T Lymphocytes in the Liver
Liver T-cells respond to the inflammatory insult generated during organ procurement and contribute to the injury following reperfusion. The mode of liver donation alters various metabolic and inflammatory pathways but the way it affects intrahepatic T-cells is still unclear. We investigated the modifications occurring in the proportion and function of T-cells during liver procurement for transplantation. We isolated hepatic mononuclear cells (HMC) from liver perfusate of living donors (LD) and donors after brain death (DBD) or cardiac death (DCD) and assessed the frequency of T-cell subsets, their cytokine secretion profile and CD8 T-cell cytotoxicity function, responsiveness to a danger associated molecular pattern (High Mobility Group Box1, HMGB1) and association with donor and recipient clinical parameters and immediate graft outcome. We found that T-cells in healthy human livers were enriched in memory CD8 T-cells exhibiting a phenotype of non-circulating tissue-associated lymphocytes, functionally dominated by more cytotoxicity and IFN-γ-production in DBD donors, including upon activation by HMGB1 and correlating with peak of post-transplant AST. This liver-specific pattern of CD8 T-cell was prominent in DBD livers compared to DCD and LD livers suggesting that it was influenced by events surrounding brain death, prior to retrieval. Mode of liver donation can affect liver T-cells with increased liver damage in DBD donors. These findings may be relevant in designing therapeutic strategies aimed at organ optimization prior to transplantation.
- 25 May 2010
- Published by Wiley in World Journal of Surgery
- Vol. 34 (9) , 2128-2132
Pancreaticoduodenectomy After Liver Transplantation in Patients with Primary Sclerosing Cholangitis Complicated by Distal Pancreatobiliary Malignancy
Background: The aim of this study was to examine the use of pancreaticoduodenectomy for malignancy in patients who have undergone liver transplantation for primary sclerosing cholangitis (PSC).Methods: Patients who underwent simultaneous or sequential pancreaticoduodenectomy after liver transplantation were identified from a prospective transplant database. Preoperative, perioperative, and follow‐up data were collected by review of patients’ medical records.Results: Four patients with PSC underwent simultaneous (1) or sequential (3) pancreaticoduodenectomy for the treatment of distal cholangiocarcinoma (2) or pancreatic adenocarcinoma (2). Postoperative complications occurred in two patients (1 pneumonia and 1 wound infection). Tumour resection margins were negative in all cases. Two patients with node‐negative tumours were disease‐free after 5 years and 23 months, and two patients with node‐positive tumours died of recurrence after 5 and 10 months.Conclusions: Pancreaticoduodenectomy after liver transplantation can be performed with low morbidity in specialist centres with expertise in both liver transplantation and major pancreatic surgery. Patients with resectable disease should be treated aggressively, although long‐term results will be dictated by the histological stage of the tumour, particularly lymph node status.
- 25 May 2010
- Published by Wiley in World Journal of Surgery
- Vol. 34 (9) , 2128-2132
Pancreaticoduodenectomy After Liver Transplantation in Patients with Primary Sclerosing Cholangitis Complicated by Distal Pancreatobiliary Malignancy
Background: The aim of this study was to examine the use of pancreaticoduodenectomy for malignancy in patients who have undergone liver transplantation for primary sclerosing cholangitis (PSC).Methods: Patients who underwent simultaneous or sequential pancreaticoduodenectomy after liver transplantation were identified from a prospective transplant database. Preoperative, perioperative, and follow‐up data were collected by review of patients’ medical records.Results: Four patients with PSC underwent simultaneous (1) or sequential (3) pancreaticoduodenectomy for the treatment of distal cholangiocarcinoma (2) or pancreatic adenocarcinoma (2). Postoperative complications occurred in two patients (1 pneumonia and 1 wound infection). Tumour resection margins were negative in all cases. Two patients with node‐negative tumours were disease‐free after 5 years and 23 months, and two patients with node‐positive tumours died of recurrence after 5 and 10 months.Conclusions: Pancreaticoduodenectomy after liver transplantation can be performed with low morbidity in specialist centres with expertise in both liver transplantation and major pancreatic surgery. Patients with resectable disease should be treated aggressively, although long‐term results will be dictated by the histological stage of the tumour, particularly lymph node status.